Your session is about to expire
← Back to Search
Radiation Therapy
SABR for Metastatic Cancer
Phase 1
Waitlist Available
Led By Glenn Bauman, MD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Brain: Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) for tumor sites with propensity for brain metastasis. All patients with brain metastases (at enrollment or previously treated) require an MRI of the brain.
Presence of poly-metastatic disease, defined as total number of targets greater than 10
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
Study Summary
This trial will test the safety of a new radiation treatment, SABR, for people with cancer that has spread to multiple sites in the body (poly-metastatic disease).
Who is the study for?
This trial is for adults with poly-metastatic cancer, meaning they have more than 10 sites of cancer in their body. They should not be pregnant or breastfeeding, must have a life expectancy over 3 months, and cannot start new systemic therapies within 6 weeks after radiotherapy. Patients with severe liver or kidney dysfunction, large brain metastases, or certain medical conditions that preclude radiotherapy are excluded.Check my eligibility
What is being tested?
The ARREST study tests the safety of Stereotactic Ablative Radiotherapy (SABR) on patients with poly-metastatic disease. SABR delivers high-dose radiation precisely to small areas and may reduce side effects by limiting exposure to healthy tissue. This phase I trial will determine if it's safe for those who have widespread cancer beyond what's currently treated with SABR.See study design
What are the potential side effects?
Potential side effects include typical reactions from high-dose radiation such as skin irritation at the treatment site, fatigue, nausea, and potential damage to nearby organs depending on where the radiation is targeted. The precise nature of SABR aims to minimize these effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have had a brain scan for my cancer that tends to spread to the brain.
Select...
My cancer has spread to more than 10 different places in my body.
Select...
I am 18 years old or older.
Select...
I can take care of myself and am up and about more than half of the day.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Maximally Tolerated Dose of Stereotactic Radiotherapy
Secondary outcome measures
Progression free survival post radiotherapy
Quality of life at 6 weeks post radiotherapy as measured by the EuroQOL Group EQ-5D-5L
Quality of life at 6 weeks post radiotherapy as measured by the Functional Assessment of Cancer Therapy - General (FACT-G)
Trial Design
5Treatment groups
Experimental Treatment
Group I: Dose Level 4Experimental Treatment1 Intervention
Group II: Dose Level 3Experimental Treatment1 Intervention
Group III: Dose Level 2Experimental Treatment1 Intervention
Group IV: Dose Level 1Experimental Treatment1 Intervention
Group V: De-escalation LevelExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Lawson Health Research InstituteLead Sponsor
656 Previous Clinical Trials
413,380 Total Patients Enrolled
Ontario Institute for Cancer ResearchOTHER
23 Previous Clinical Trials
9,137 Total Patients Enrolled
Glenn Bauman, MDPrincipal InvestigatorLondon Health Sciences Centre, Lawson Health Research Institute
7 Previous Clinical Trials
379 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have signs of pressure on my spinal cord.My cancer has spread, and this was confirmed by tests.My cancer has spread to the brainstem.My liver is not working well due to cancer spread.My doctor believes all my cancer sites can be safely treated.I have not used certain cancer drugs 2 weeks before radiation but may continue hormone therapy.I have had a brain scan for my cancer that tends to spread to the brain.My cancer has spread to more than 10 different places in my body.I am 18 years old or older.I have had radiation before, but it doesn't overlap much with the new treatment area.My blood counts are too low for safe radiation treatment.I have more than 50 cancer spots, not counting tiny ones under 5mm.I have no standard treatment options left, refuse them, or won't start any new treatments for 3 months.You are expected to live for at least 3 more months.I have previously been treated with radiopharmaceuticals like Radium 223 or Lutetium 177.I need surgery to relieve pressure in my brain from cancer spread.My kidney function is low and I am expected to receive a high dose of radiation to my kidney.I cannot treat all areas where my cancer has spread.My condition affects my digestive system, lymph nodes near my intestines, or skin.My cancer has spread widely and cannot be treated with targeted radiation.I can take care of myself and am up and about more than half of the day.My brain metastasis is not larger than 3 cm or total volume greater than 30 cc.I have a tumor larger than 5 cm that has spread from its original site.I have had the required scans for my condition.I cannot have radiotherapy due to serious health conditions like lung disease or Crohn's.My cancer is only in my brain or spinal cord.
Research Study Groups:
This trial has the following groups:- Group 1: Dose Level 1
- Group 2: Dose Level 2
- Group 3: De-escalation Level
- Group 4: Dose Level 4
- Group 5: Dose Level 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is access to this clinical trial currently available for participants?
"Affirmative. According to clinicaltrials.gov, this trial is still recruiting patients and was posted on November 17th 2020 before being updated most recently on April 4th 2022. A total of 48 volunteers are needed from a single location for the study's success."
Answered by AI
How many participants have joined the research study to date?
"Affirmative. According to clinicaltrials.gov, the trial is currently open for participation and has been since its posting on November 17th 2020. The investigation seeks 48 participants from a single site, with most recent updates posted April 4th 2022."
Answered by AI
Has the FDA given their blessing to Stereotactic ablative radiotherapy - De-escalation Level?
"The safety of Stereotactic ablative radiotherapy - De-escalation Level was rated a 1, as this Phase 1 trial has limited data regarding efficacy and security."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger